Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAK Latar belakang: Tumor sel germinal ovarium maligna (TSGOM) yang gagal sembuh dengan penatalaksanaan konvensional memiliki prognosis buruk. Beberapa kejadian rekuren setelah kemoterapi juga ditemukan. Programmed Death Ligand-1 (PD-L1) terekspresi pada berbagai keganasan dan tumor infiltrating lymphocytes (TILs) serta telah diketahui perannya sebagai faktor prognostik. Penelitian ini dilakukan untuk mengetahui peran ekspresi PD-L1 pada TSGOM dalam menentukan overall survival (OS) dan progression free survival (PFS).Bahan dan cara: Penelitian ini merupakan penelitian kohort retrospektif dengan desain analisis kesintasan. Data klinis diambil dari rekam medis RSUPN Cipto Mangunkusumo sejak Januari 2010-Desember 2016 yang diobservasi selama 2 tahun. Data histopatologik diambil dari Departemen Patologi Anatomi RSUPN Cipto Mangunkusumo yang kemudian dilakukan pulasan imunohistokimia PD-L1.Hasil: Tidak terdapat hubungan yang bermakna antara ekspresi PD-L1 pada sel tumor dan TILs dengan 2-year OS (p=0,275) dan PFS (p=0,421) pada TSGOM. Terdapat hubungan yang bermakna antara jenis histopatologik dengan 2-year OS (p=0,002) serta stadium pada 2-year OS (p=0,028) dan PFS (p=0,014).Kesimpulan: OS dan PFS tidak berhubungan dengan ekspresi PD-L1 pada sel tumor dan TILs pada TSGOM.

---

ABSTRACT

Background: The prognosis of malignant ovarian germ cell tumors (MOGCT) patients who failed to be cured with conventional therapy is poor. Several recurrent events after chemotherapy were also found. PD-L1 is expressed in various types of malignancy and tumor infiltrating lymphocytes (TILs) and its role is known as a prognostic factor. This study was conducted to determine the role of PD-L1 expression in MOGCT in determining overall survival (OS) and progression free survival (PFS).

Materials and Methods: This is a retrospective cohort study with survival analysis. Clinical data were obtained from medical record in RSUPN Cipto Mangunkusumo since January 2010-December 2016 and observed for 2 years. Histopathological data were obtained from Anatomical Pathology Department and PD-L1 immunohistochemistry staining were performed.

Results: No significant correlation between PD-L1 expression in tumor cells and TILs with 2-year OS (p=0,275) and PFS (p=0,421) in MOGCT. A significant correlation between histopathologic type and 2-year OS (p=0,002) was found. We also found significant correlations between stage and survival outcomes 2-year OS (p=0,028) and PFS (p=0,014).

Conclusion: OS and PFS were not significantly correlated with PD-L1 expression in tumor cells and TILs in MOGCT."

""Now thoroughly updated to include new advances in the field, and with regular content updates to the eBook, Principles and Practice of Pediatric Oncology, 7th Edition remains the gold standard text for the care and research of children with cancer. This authoritative reference is the single most comprehensive resource on the biology and genetics of childhood cancer and the diagnosis, multimodal treatment, and long-term management of young patients with cancer. Also addressed are a broad array of topics on the supportive and psychosocial aspects of care of children and families. Covering virtually every aspect of the breadth and depth of childhood cancer, this 7th Edition provides expert guidance on state-of-the-art, multidisciplinary care for children and families"--Publisher's description."

"This book presents many of the major, relevant advances in molecular pathology that are occurring in the field of pediatric oncology and will serve as a useful overview for resident and attending physicians as well as scientists interested in understanding the molecular pathology of pediatric cancer in the context of clinical medicine. Chapters are based upon organ systems, and each is written by an expert or pair of experts in their field with subspecialty training and extensive clinical experience. Each chapter describes a variable number of tumors and includes an overview of the classification system and clinicopathological characteristics of each tumor. This is followed by a discussion of the molecular pathology relevant to a specific tumor, including specific molecular markers of the tumors, methods used for diagnosis or clinical management, clinical significance of the markers, and if appropriate, a description or discussion of current activities in translational research or issues that need to be addressed in the future. "

"This third volume of the Springer series discussing pediatric cancer focuses on diagnosing, treating, and assessing the future course of malignant brain neoplasms in children. In addition to a general introduction to the principals involved, the material includes vital research in molecular genetics, a major contribution to the molecular characterization of solid tumors, which will define new biomarkers of the disease and identify molecular pathways. The volume includes presentations of present and future therapies. The volume also explains AT/RT’s dissemination to the cerebral fluid, the molecular mechanisms underlying the progression of medulloblastoma, and the importance of gamma knife radiosurgery during multimodality management of medulloblastoma/PNET tumors. Other topics discussed include using magnetic resonance imaging for diagnosing retinoblastoma, and mapping the effects of radiotherapy in low-grade glioma in children. Information on alterations in cell-cycle regulators that are influenced by tumor suppressor genes and oncogenes is detailed. Contributors provide recommendations concerning non-narcotic analgesic routines for children recovering from cranial and spinal surgery. "

"Latar belakang: Penyakit kanker pada anak masih memiliki angka kematian yang tinggi. Pandemi Coronavirus disease 2019 (COVID-19) dapat memperlebar kesenjangan luaran pasien kanker anak di negara berkembang dengan negara maju. Data mengenai pasien kanker anak dengan COVID-19 terkonfirmasi di negara berkembang masih terbatas.Tujuan: Mengetahui prevalens dan luaran pasien kanker anak dengan COVID-19 terkonfirmasi serta faktor yang memengaruhinya agar luaran kanker dapat optimal.Metode: Penelitian ini merupakan studi prognostik dengan desain penelitian kohort retrospektif di rumah sakit rujukan nasional menggunakan data rekam medis. Subyek penelitian adalah pasien kanker anak usia 0-18 tahun dengan COVID-19 terkonfirmasi yang dirawat di pusat COVID-19 - RSCM pada Maret 2020 – Juni 2023. Data deskriptif mengenai prevalens, karakteristik, dan luaran dikumpulkan, dilakukan juga analisis untuk mengetahui pengaruh antara jenis kanker, fase pengobatan, penundaan pengobatan, dan derajat keparahan COVID-19 terhadap luaran.Hasil: Dari 585 pasien kanker anak yang dirawat, 110 (18,8%) di antaranya terkonfirmasi COVID-19 berdasarkan swab PCR SARS-COV-2. Pasien mayoritas berusia 0-5 tahun (39,1%), menderita kanker darah (50,9%), dalam fase pengobatan (88,1%), dan pengobatan tersebut tertunda sebanyak 56,4%. Gejala tersering adalah demam (78,2%), nilai CT PCR terbanyak terdeteksi di bawah 30 (54,6%), dan mayoritas mengalami COVID-19 derajat ringan (55,5%). Tata laksana yang diberikan adalah terapi oksigen (29,1%) dengan penggunaan ventilator sebanyak 8,2% dan dirawat di PICU sebanyak 12,7%, pemberian antivirus (69,1%), antibiotik (80,9%), antiinflamasi (14,5%), dan antikoagulan (22,7%). Sebanyak 19,1% kasus meninggal dan mayoritas terjadi pada 14 hari pertama perawatan. Kesintasan kumulatif adalah 66,1% dan rerata kesintasan selama 40 hari (IK 95% 33,743-46,064). Jenis kanker, fase pengobatan, dan penundaan pengobatan tidak berpengaruh bermakna terhadap luaran kematian. Sementara, derajat keparahan COVID-19 berpengaruh bermakna terhadap luaran kematian dengan HR 4,38 (IK 95% 1,34-14,26; p=0,000) pada derajat sedang/berat dan HR 16,29 (IK 95% 4,83-54,8; p=0,014) pada derajat kritis.Simpulan: Prevalens dan angka kematian pasien kanker anak dengan COVID-19 terkonfirmasi lebih tinggi dibanding COVID-19 pada anak secara keseluruhan, terutama di negara berkembang. Penundaan kemoterapi dapat dipertimbangkan, terutama dalam 14 hari pertama perawatan di rumah sakit.

---

Background: Pediatric cancer still has a high mortality rate. The Coronavirus disease 2019 (COVID-19) pandemic has further widened the disparity in pediatric cancer outcomes between developing and developed countries. Limited data exist on the prevalence and consequences of pediatric cancer with confirmed COVID-19 in developing countries.

Objectives: To determine the prevalence and outcomes of these patients and identify influencing factors to optimize cancer outcomes.

Method: This prognostic study employed a retrospective cohort design at a tertiary referral hospital in Indonesia using medical record data. Subjects included pediatric cancer patients aged 0-18 years with confirmed COVID-19 treated at the Kiara COVID-19 Center – dr. Cipto Mangunkusumo Hospital from March 2020 to June 2023. Descriptive data on prevalence, characteristics, and outcomes were collected, along with analysis of the relationship between cancer type, treatment phase, delayed treatment, and COVID-19 severity.

Result: Among 585 pediatric cancer patients treated, 110 (18.8%) were confirmed COVID-19 based on SARS-COV-2 PCR. The majority were aged 0-5 years (39,1%), diagnosed with blood cancer (50,9%), undergoing radio-chemotherapy (88,1%), and delayed treatment 56,4%. Fever was the most prevalent symptom (78.2%), the most CT PCR values were below 30 (54,6%), with 55,5% experiencing mild COVID-19. Management included oxygen therapy (29,1%) with ventilator use (8.2%) and intensive care (12.7%), antiviral (69.1%), antibiotic (80.9%), anti-inflammatory (14.5%), and anticoagulant (22.7%). The mortality rate was 19,1% and the highest number of deaths occurred within 14 days of hospitalization. Cumulative survival was 66.1% and a mean survival was 40 days (95% CI 33.743-46.064). Cancer type, treatment phase, and delayed treatment were not association with mortality outcomes. Meanwhile, COVID-19 severity was associated with mortality outcomes with HR 4.38 (95% CI 1.34-14.26; p=0.000) in moderate/severe COVID-19 and 16.29 (95% CI 4.83-54.8; p=0.014) in critical case.

Conclusion: The prevalence and mortality rates of pediatric cancer with confirmed COVID-19 are notably higher than the general pediatric COVID-19, especially in developing countries. Chemotherapy may be considered postponed, particularly within the first 14 days of hospitalization."

"Pediatric oncology is a considerably complex discipline requiring frequent need for reference material. Emergencies in Pediatric Oncology meets this objective by serving as a concise, practical resource for the hurried physician. Replete with diagrams and written in a clear, succinct style, this title offers an easy-to-read guide especially useful for residents, fellows, and nurses. Providing an overview of the epidemiology of childhood cancer and the history of its treatment, this title also addresses a range of key problems in the pediatric oncologic setting, covering the most common emergencies and providing short, practical guidelines on how to handle them. Written by authorities from an array of disciplines, this helpful resource provides answers and concrete guidance and is a valuable contribution to the literature in pediatric oncology."

"This is the first book to be devoted exclusively to rare tumors in children and adolescents, and its aim is to provide up-to-date information on their diagnosis and clinical management. The opening section addresses general issues including epidemiology, risk factors/etiology, biology and genetics, early detection, and screening. It also discusses solutions to assist in the management of rare tumors, such as international networking and internet platforms. In the second section, specific malignancies are described, with practical guidance on diagnostic workup, multimodal therapy, follow-up, and adverse effects. Discussion of differential diagnosis encompasses both frequent and rare tumor types, which should enable the clinician to take rare entities into account during the diagnostic assessment. Each chapter goes on to provide detailed therapeutic guidelines for specific rare tumors. The authors are a multidisciplinary group of specialists who have dedicated themselves to this group of tumors."